Latest Breaking News On - Autosomal dominant polycystic kidney disease - Page 6 : comparemela.com

Mironid appoints Dr Catherine Kelleher as Chief Medical Officer

Regulus Reports Positive Topline Data From First Cohort Of Patients In Phase 1b Study Of RGLS8429

(RTTNews) - Regulus Therapeutics Inc. (RGLS) reported positive topline results from the first cohort of patients in Phase 1b MAD study of RGLS8429.

Mironid extends Series A round raising £35 million to date

Roche Venture Fund joins existing major investors Epidarex Capital, Sofinnova Partners and BioGeneration Ventures September 13, 2023: Glasgow, Scotland.

Mironid extends Series A round raising £35 million to date for development of first-in-class small molecules to treat life-threatening hereditary kidney disease

Regulus Therapeutics Up 8% On Completion Of Enrollment In Second Cohort Of Phase 1b MAD Trial

Regulus Therapeutics Inc. (RGLS) saw an 8% increase in its shares on Wednesday after announcing the completion of patient enrollment in the second cohort of the Phase 1b Multiple-Ascending Dose (MAD) study of RGSL8429 for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD).